Abstract
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.
Author supplied keywords
Cite
CITATION STYLE
APA
Akinleye, A., Iragavarapu, C., Furqan, M., Cang, S., & Liu, D. (2015). Novel agents for advanced pancreatic cancer. Oncotarget, 6(37), 39521–39537. https://doi.org/10.18632/oncotarget.3999
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free